We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oncology Drug Reference Sheet: Venetoclax (Venclexta®).
- Authors
Lubejko, Barbara
- Abstract
The article offers information on Venetoclax approved by the U.S. Food and Drug Administration (FDA) in 2018 for use in combination therapy for acute myeloid leukemia (AML) in older adults and in May 15, 2019 for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients as a single agent or in combination therapy. Topics covered include dosing schedule, adverse reactions, and considerations for nurses before beginning venetoclax therapy.
- Subjects
VENETOCLAX; ANTINEOPLASTIC agents; ONCOLOGY nursing; CHRONIC lymphocytic leukemia; GERIATRIC nursing; ORAL drug administration; PATIENT education; UNITED States. Food &; Drug Administration; DRUG approval; ACUTE myeloid leukemia; SIGNAL peptides; CHEMICAL inhibitors; ADULTS; OLD age
- Publication
ONS Voice, 2019, Vol 34, Issue 8, p24
- ISSN
2475-6938
- Publication type
Article